ReviewDrug design, development and therapy2022

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.

Hikmat Abdel-Razeq et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.